We Develop Complex Formulations Utilizing Our Know-How and Proprietary Technologies

Our products have effectively met the medical needs of patients worldwide, with Lidoderm (a non-opioid 5% Lidocaine Patch) playing a significant role in alleviating the suffering of individuals living with pain associated with Post Herpetic Neuralgia, but our teams are continuing to develop innovative products to address unmet needs in the market. As a California-based pharmaceutical company, we are known for developing and manufacturing complex formulations entirely in-house that are difficult to replicate.

OUR HISTORY

Teikoku Seiyaku has a storied history of technological innovation and business success.

1848
1918
1938
1957
1974
1988
1988
1993
1995
1997
1999
2000
2003
2007
2014
2017
2017
2022

1848

Shozo Akazawa, the 5th head of the family, is certified by the government to deal in medicines, and starts the business.

1918

Teikoku Seiyaku is established with 1 million yen in capital in Kagawa Prefecture, Japan.

1938

Horxis launches in Japan, a prototype of the current medicated plaster.

1957

Osaka Plant spins off of Teikoku Seiyaku, and with it, Fuso Chemical Industry Co. Ltd.

1974

Teikoku Seiyaku’s medicated plasters are approved for prescription use in Japan, becoming the company’s main product line.

1988

Catlep, Japan’s first transdermal indomethacin plaster for prescription use, is approved and production begins.

1988

New plant (now Plant No. 2), 5 stories and 6,451 square meters, completed at the site of headquarters complex.

1993

Seltouch®, a transdermal felbinac plaster for prescription use, is approved in Japan and production begins.

1995

Non-prescription drug division (OTC) spins off as an independent company, Teikoku Pharmacare, Co. Ltd.

1997

Teikoku Pharma USA is established as a California pharmaceutical company.

1999

FDA grants approval for Lidoderm in the US.

2000

Completion of Plant No. 8 to manufacture topical poultice and matrix plasters.

2003

Fuso Teiyaku is established in Qingdao, China.

2007

Versatis receives MHRA approval in UK, and Flector receives FDA approval in the US.

2014

Completion of Plant No. 9 to manufacture matrix plasters.

2017

Approval of Rupafin® in Japan

2017

Completion of Plant No. 10 to manufacture ointment and cream.

2022

Approval of ALLYDONE® in Japan

CONTACT US

Contact us for distribution or licensing opportunities, or to learn more about our growing portfolio of life-changing drug therapies.

"*" indicates required fields

Policy*